Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases

• US 10,640,573 B2
• Filed: 10/05/2018
• Issued: 05/05/2020
• Est. Priority Date: 10/15/2013
• Status: Active Grant

• Current Assignee: GeneFrontier Corporation (Kaneka Corporation)
• Original Assignee: GeneFrontier Corporation (Kaneka Corporation)
• Inventors: Miyakoshi, Akira, Nakamura, Mikiko, Kojoh, Kanehisa, Mochizuki, Satsuki, Okada, Yasunori
• Primary Examiner(s): Haddad, Maher M
• Application Number:
  US16/153,413
• Publication Number:
  US 20190233541A1
• Time in Patent Office: Days
• Field of Search: None
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.

Claims

1. An antibody comprising a light chain variable region and a heavy chain variable region,

wherein the light chain variable region comprises:

CDR1 comprising the amino acid sequence of SEQ ID NO;

1;

CDR2 comprising the amino acid sequence of SEQ ID NO;

2; and

CDR3 comprising the amino acid sequence of SEQ ID NO;

3, and

wherein the heavy chain variable region comprises;

CDR1 comprising the amino acid sequence of SEQ ID NO;

4;

CDR2 comprising the amino acid sequence of SEQ ID NO;

5; and

CDR3 comprising the amino acid sequence of SEQ ID NO;

6, wherein the antibody specifically binds human ADAMTS4.

2. The antibody according to claim 1,

wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:

7, and

wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO;

8.

3. The antibody according to claim 1, wherein the antibody inhibits aggrecanase activity of the human aggrecanase.

4. The antibody according to claim 1, wherein the antibody further inhibits aggrecanase activity of human ADAMTS5.

5. The antibody according to claim 1,

wherein the antibody binds to an epitope of a human aggrecanase, and

wherein the epitope consists of 20 or less amino acid residues and comprises the amino acid sequence of SEQ ID NO:

9.

6. The antibody according to claim 5, wherein the epitope consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:

9-13.

7. A pharmaceutical composition comprising the antibody according to claim 1.